Dovitinib was investigated in combination with fulvestrant in postmenopausal women with hormone receptor (HR)-positive, HER2-negative, FGFR (FGFR1, FGFR2, or FGF3)-amplified breast cancer who progressed on endocrine therapy in a phase II trial [139]. Here, FGFR2 is linked to breast cancer.